Gilead to Donate Experimental Coronavirus Drug Remdesivir (2)

Gilead Sciences Inc. said it’s donating 1.5 million doses of its experimental anti-coronavirus drug remdesivir, which could treat 140,000 patients.

The drug will be offered for compassionate use, expanded access and clinical trials, and will treat patients with severe symptoms, Chairman and Chief Executive Officer Daniel O’Day said in an open letter. The company is also boosting its supply of remdesivir to more than 500,000 treatment courses by October, and to more than 1 million by the end the year. Production time has also been accelerated to six months from one year, he said.

Daniel O’Day attends a meeting in Washington, D.C. on March 2.

Photographer: Kevin Dietsch/UPI/Bloomberg

“While we are working ...